Wave Life Sciences Sets Oct. 27, 2026 Q3 Review, Expects WVE-006 Data in Q4 2026
Photo: TokenPost
Wave Life Sciences will review third-quarter 2026 results and provide business updates on Tuesday, Oct. 27. The company expects fourth-quarter data for WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency. At June 30, cash, cash equivalents and marketable securities totaled $490.6 million. The balance was expected to fund operations into the third quarter of 2028. Second-quarter revenue was $2.272 million, compared with $8.699 million in the year-earlier quarter. Wave's Oct. 1 plan outlines a two-year registrational trial for WVE-006. A one-year interim analysis could support potential accelerated approval.
Source: TokenPost
